Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX

Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 127.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,325 shares of the company’s stock after buying an additional 13,617 shares during the period. Bridgefront Capital LLC’s holdings in Vaxcyte were worth $876,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd acquired a new stake in Vaxcyte in the third quarter worth about $45,000. CWM LLC increased its holdings in shares of Vaxcyte by 55.1% during the third quarter. CWM LLC now owns 2,606 shares of the company’s stock valued at $94,000 after acquiring an additional 926 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of Vaxcyte by 45.8% during the second quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock valued at $89,000 after acquiring an additional 857 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Vaxcyte by 96.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock valued at $117,000 after purchasing an additional 1,596 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its stake in Vaxcyte by 110.8% in the 2nd quarter. Osaic Holdings Inc. now owns 3,859 shares of the company’s stock worth $128,000 after purchasing an additional 2,028 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 9,743 shares of the stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the sale, the insider directly owned 23,928 shares of the company’s stock, valued at approximately $1,117,198.32. This trade represents a 28.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Elvia Cowan sold 2,500 shares of Vaxcyte stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $58.59, for a total value of $146,475.00. Following the transaction, the chief accounting officer owned 30,867 shares of the company’s stock, valued at $1,808,497.53. The trade was a 7.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,261 shares of company stock worth $1,593,767 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Needham & Company LLC boosted their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Guggenheim reaffirmed a “buy” rating and issued a $116.00 price target on shares of Vaxcyte in a report on Monday, February 2nd. Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, January 9th. Finally, Leerink Partners set a $77.00 target price on Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $94.50.

Vaxcyte Stock Down 2.9%

Vaxcyte stock opened at $54.58 on Monday. The stock has a 50-day moving average price of $54.08 and a 200 day moving average price of $46.01. The company has a market capitalization of $7.86 billion, a price-to-earnings ratio of -9.71 and a beta of 1.31. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $76.61.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same period in the prior year, the business posted ($1.12) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.